ReviewGynecologic oncology2022
Increasing global accessibility to high-level treatments for cervical cancers.
Review in Gynecologic oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Centralization of MR image-guided adaptive brachytherapy for cervical cancer in Austria: feasibility and outcomes.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- Performance of the cervical cancer screening program in Souss-Massa, Morocco: evidence for strategic transition toward HPV testing.BMC women's health · 2026Article
- Multiple-level stakeholders' perspectives on barriers and facilitators of HPV vaccination delivery in Western and Central Kenya: a qualitative study.BMJ public health · 2026Article
- Metal artifact reduction in spectral computed tomography for intracavity brachytherapy in cervical cancer patients: a prospective study.Radiation oncology (London, England) · 2025Article
- Sexual Satisfaction and Psychosocial Well-Being Among Saudi Survivors of Cervical and Breast Cancer: A Cross-Sectional Analysis.Healthcare (Basel, Switzerland) · 2025Article
- Assessing delays in accessing and completing radiotherapy for cervical cancer treatment: A multicenter survey of oncology providers in go further-funded countries in Sub-Saharan Africa.Gynecologic oncology reports · 2025Article
- Efficacy of induction chemotherapy during the COVID-19 pandemic for treatment of locally advanced cervical cancer in Botswana.Gynecologic oncology · 2025Observational
- A nomogram model to predict grade ≥2 acute radiation enteritis in older adult patients with cervical cancer.Frontiers in public health · 2025Article
- Validity of the process and outcome specific measure in women with abnormal Papanicolaou screening test.PloS one · 2025Article
- Article
- From barriers to opportunities from COVID-19 pandemic: Stakeholder perspectives on cervical cancer screening programs in LMICs of the Asia-Pacific region.PLOS global public health · 2024Article
- Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis.Frontiers in pharmacology · 2024Article
- The recovery strategies to support cervical cancer elimination in lower-and middle-income countries (LMICs) following COVID-19 disruptions.Preventive medicine reports · 2023Review
- Global cancer surgery in low-resource settings: A strengths, weaknesses, opportunities, and threats analysis.Cancer · 2023Review
- Feasibility of outpatient hybrid brachytherapy for cervical cancer with minimal sedation: Results from a single-institutional protocol.Journal of contemporary brachytherapy · 2023Article
- RGS1 and related genes as potential targets for immunotherapy in cervical cancer: computational biology and experimental validation.Journal of translational medicine · 2022Article
- Review
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 9 institutions in 5 countries.
Funding
Abstract
Human papillomaviruses (HPV)-related gynecological cancers are a major health care issue, and a leading cause of cancer death in low- and middle-income countries (LMIC). In 2020, the World Health Organization launched a program aimed at cervical cancer elimination, by screening and vaccination strategies. Offering the best possible care to women diagnosed with invasive cancer is a complementary objective. Treatment of cervical cancer as per modern standards is complex and multimodal, mainly relying on surgery, external-beam radiotherapy (+/-chemotherapy) and brachytherapy. In parallel with the pivotal role of multidisciplinary discussion, international societies provide guidance to define the most effective and least toxic anti-cancer strategy, homogenize treatment protocols and provide benchmark quality indicators as a basis for accreditation processes. The challenge is to offer the appropriate diagnostic workup and treatment upfront and to avoid non- evidence-based treatment that consumes resources, impairs quality of life (QoL), and compromises oncological outcome. Various strategies may be applied for improving treatment quality: development of surgical mentorship, companion-training programs and international cooperation. The lack of radiotherapy/brachytherapy facilities is a major concern in LMIC. Reinforcing international support in terms of education, training, research and development and technical cooperation with national projects is required to increase access to minimum requirements but also introduce modern techniques, upgrade radiotherapy/brachytherapy services, and expand access to modern systemic treatments. In countries with robust economies, compliance to standards should also be increased. Integrative cancer care and multidisciplinary approaches are needed to tackle the dual challenge of increasing cure rates while minimizing QoL impairment. Appropriate dimensioning of the resources to avoid harmful treatment delays and access to expert referral centers is also a priority.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.